- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced (unresectable) Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C hepatocellular carcinoma
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Nivolumab; Ipilimumab – July 2025
Nivolumab (liver cancer) ; Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®; Ipilimumab (liver cancer); Injection concentrate for I.V. infusion 50 mg in 10 mL; Yervoy®
Last updated
9 July 2025